<DOC>
	<DOCNO>NCT00104858</DOCNO>
	<brief_summary>This phase II trial study well fludarabine phosphate radiation therapy rituximab follow donor stem cell infusion work treat patient high-risk chronic lymphocytic leukemia ( CLL ) small lymphocytic lymphoma ( SLL ) low side effect . Nonmyeloablative stem cell transplant use low dos chemotherapy ( fludarabine phosphate ) radiation suppress patient 's immune system enough prevent rejection donor 's stem cell . Following infusion donor stem cell , mixture patient 's donor 's stem cell exist call `` mixed chimerism '' . Donor cell attack patient 's leukemia . This call `` graft-versus-leukemia '' effect . Rituximab give 3 day three time infuse stem cell help control CLL early transplant till `` graft-versus-leukemia '' take control . Further , rituximab could augment `` graft-versus-leukemia '' effect activate donor immune cell hence improve disease control . Sometimes transplanted cell donor also attack body 's normal cell . Giving cyclosporine mycophenolate mofetil transplant may stop happening .</brief_summary>
	<brief_title>Fludarabine Phosphate , Radiation Therapy , Rituximab Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed Rituximab High-Risk Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine whether nonmyeloablative conditioning allogeneic hematopoietic cell transplantation ( HCT ) improve survival 18 month patient fludarabine ( fludarabine phosphate ) -refractory , fludarabine/cyclophosphamide/rituximab ( FCR ) -failed , del 17p CLL historical control ( 45 % 18 month ) give CAMPATH-1H ( alemtuzumab ) . SECONDARY OBJECTIVES : I . Estimate overall response rate ( complete remission [ CR ] + partial remission [ PR ] ) standard morphologic , flow cytometric , molecular technique . II . Assess rate relapse/progression . III . Define incidences regimen-related toxicity ( RRT ) infection within first 100 day incidence transplant-related mortality ( TRM ) within first year . IV . Estimate incidence grade II-III III-IV acute graft-versus-host disease ( GVHD ) chronic GVHD . V. Determine whether addition rituximab nonmyeloablative conditioning allogeneic HCT improve survival 18 month historical data ( 57 % 18 month ) . VI . Determine incidence serious adverse event addition rituximab comparison historical data unrelated nonmyeloablative HCT . VII . Evaluate pharmacokinetics rituximab . VIII . Evaluate B-cell T-cell immune reconstitution comparison historical data unrelated nonmyeloablative HCT . IX . Describe donor host polymorphism FCgammaRIIIa receptor cluster differentiation ( CD ) 32 evaluate impact disease response relapse . X . Investigate mechanism disease resistance relapsed/nonresponding patient . XI . Isolate donor cytotoxic T lymphocytes specific host minor histocompatibility antigen . OUTLINE : Patients receive condition regimen comprise fludarabine phosphate intravenously ( IV ) day -4 -2 rituximab IV day -3 , 10 , 24 , 38 . Patients undergo single fraction low-dose total-body irradiation ( TBI ) day 0 . After completion TBI , patient undergo allogeneic hematopoietic stem cell transplantation ( HSCT ) day 0 . Patients receive rituximab IV day 10 , 24 , 38 . Patients receive immunosuppressive regimen comprise cyclosporine orally ( PO ) twice daily ( BID ) day -3 56 follow taper day 180 ( related recipient ) day -3 100 follow taper day 180 ( unrelated recipient ) . Patients also receive mycophenolate mofetil PO BID day 0-27 ( related recipient ) three time daily ( TID ) day 0-40 followed taper day 96 ( unrelated recipient ) . After completion study treatment , patient follow 6 month , 1 year , 18 month , 2 year , annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Leukemia , Large Granular Lymphocytic</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients diagnosis CLL ( SLL ) diagnosis CLL progress prolymphocytic leukemia ( PLL ) Patients BCell CLL PLL : Failed meet National Cancer Institute ( NCI ) Working Group criteria 2 complete partial response 2 cycle therapy regimen contain fludarabine ( another nucleoside analog , e.g . cladribine [ 2CDA ] , pentostatin ) disease relapse within 12 month complete therapy fludarabine ( another nucleoside analog ) contain regimen Failed FCR pentostatin/cyclophosphamide/rituximab ( PCR ) combination chemotherapy time point Patients novo acquire `` 17p deletion '' cytogenetic abnormality ; patient receive induction treatment could transplant 1st CR Patients suitable human leukocyte antigen ( HLA ) match related unrelated donor willing receive filgrastim ( GCSF ) , undergo leukapheresis collect peripheral blood mononuclear cell ( PBMC ) , donate stem cell RELATED DONORS : When one potential donor exists , priority give donor base HLA identity &gt; cytomegalovirus ( CMV ) seronegativity &gt; ABO compatibility &gt; sex match Donor HLA phenotypically genotypically identical allele level HLAA , B , C , DRB1 , DQB1 Must consent GCSF administration leukapheresis ; Must adequate vein leukapheresis agree placement central venous catheter ( femoral , subclavian ) ; Only GCSF mobilize PBMC permit hematopoietic stem cell ( HSC ) source protocol UNRELATED DONORS : Fred Hutchinson Cancer Research Center ( FHCRC ) matching allow Grades 1.0 2.1 ; Unrelated donor prospectively : Matched HLAA , B , C , DRB1 DQB1 high resolution type Only single allele disparity allow HLAA , B , C define high resolution type UNRELATED DONORS : Donors exclude preexist immunoreactivity identify would jeopardize donor hematopoietic cell engraftment ; determination base standard practice individual institution ; recommended procedure patient 10 10 HLA allele level ( phenotypic ) match obtain panel reactive antibody screen class I II antigens patient HCT ; PRA show &gt; 10 % activity , flow cytometric B T cell cytotoxic cross match obtain ; donor exclude cytotoxic cross match assay positive ; patient HLA Class I allele mismatch , flow cytometric B T cell cytotoxic cross match obtain regardless PRA result ; positive antidonor cytotoxic crossmatch absolute donor exclusion UNRELATED DONORS : Patient donor pair homozygous mismatch allele graft rejection vector consider twoallele mismatch , i.e. , patient A*0101 donor A*0102 , type mismatch allow UNRELATED DONORS : Only GCSF mobilize PBMC permit HSC source protocol Infection human immunodeficiency virus ( HIV ) Active diagnosis central nervous system ( CNS ) involvement CLL Patients unwilling use contraceptive technique 12 month HCT Pregnant woman females breastfeed The addition cytotoxic agent 'cytoreduction ' exception tyrosine kinase inhibitor ( imatinib mesylate ) , cytokine therapy , hydroxyurea , low dose cytarabine , chlorambucil , rituxan allow within three week initiation condition Active bacterial fungal infection unresponsive medical therapy Performance status : Karnofsky score &lt; 60 adult patient Cardiac ejection fraction &lt; 40 % ; ejection fraction require age &gt; 50 year history prior transplant , anthracycline exposure history cardiac disease ; poorly control hypertension despite multiple antihypertensive Diffusing capacity lung carbon monoxide ( DLCO ) &lt; 40 % , total lung capacity ( TLC ) &lt; 40 % , forced expiratory volume 1 second ( FEV1 ) &lt; 40 % and/or require continuous supplementary oxygen , severe deficit pulmonary function test define pulmonary consultant service ; FHCRC principal investigator ( PI ) study must approve enrollment patient pulmonary nodule Patients clinical laboratory evidence liver disease would evaluate cause liver disease , clinical severity term liver function , degree portal hypertension ; patient exclude find fulminant liver failure , cirrhosis liver evidence portal hypertension , hepatic damage bridge fibrosis , alcoholic hepatitis , esophageal varix , history bleed esophageal varix hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evidence prolongation prothrombin time , ascites related portal hypertension , bacterial fungal liver abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3 mg/dl , symptomatic biliary disease Patients active nonhematologic malignancy ( except nonmelanoma skin cancer ) ; exclusion apply patient nonhematologic malignancy require therapy Patients history nonhematologic malignancy ( except nonmelanoma skin cancer ) currently complete remission , less 5 year time complete remission , &gt; 20 % risk disease recurrence ; exclusion apply patient nonhematologic malignancy require therapy DONOR : Age &lt; 12 year DONOR : Identical twin DONOR : Pregnancy DONOR : Infection HIV DONOR : Inability achieve adequate venous access DONOR : Known allergy filgrastim ( GCSF ) DONOR : Current serious systemic illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>